Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/TAOK1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/TAOK1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/TAOK1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/TAOK1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TAOK1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TAOK1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TAOK1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/TAOK1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/TAOK1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TAOK1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005140319 | Skin | AK | stress-activated MAPK cascade | 48/1910 | 239/18723 | 3.43e-06 | 8.82e-05 | 48 |
GO:003287218 | Skin | AK | regulation of stress-activated MAPK cascade | 41/1910 | 192/18723 | 3.57e-06 | 8.96e-05 | 41 |
GO:19019877 | Skin | AK | regulation of cell cycle phase transition | 69/1910 | 390/18723 | 3.69e-06 | 9.11e-05 | 69 |
GO:007030218 | Skin | AK | regulation of stress-activated protein kinase signaling cascade | 41/1910 | 195/18723 | 5.36e-06 | 1.24e-04 | 41 |
GO:003109819 | Skin | AK | stress-activated protein kinase signaling cascade | 48/1910 | 247/18723 | 8.76e-06 | 1.89e-04 | 48 |
GO:190290419 | Skin | AK | negative regulation of supramolecular fiber organization | 35/1910 | 167/18723 | 2.73e-05 | 4.77e-04 | 35 |
GO:00427709 | Skin | AK | signal transduction in response to DNA damage | 35/1910 | 172/18723 | 5.20e-05 | 8.05e-04 | 35 |
GO:00064736 | Skin | AK | protein acetylation | 39/1910 | 201/18723 | 6.08e-05 | 9.02e-04 | 39 |
GO:004632810 | Skin | AK | regulation of JNK cascade | 29/1910 | 133/18723 | 6.10e-05 | 9.02e-04 | 29 |
GO:004677714 | Skin | AK | protein autophosphorylation | 42/1910 | 227/18723 | 1.01e-04 | 1.33e-03 | 42 |
GO:00457866 | Skin | AK | negative regulation of cell cycle | 63/1910 | 385/18723 | 1.08e-04 | 1.40e-03 | 63 |
GO:003367424 | Skin | AK | positive regulation of kinase activity | 73/1910 | 467/18723 | 1.42e-04 | 1.71e-03 | 73 |
GO:00705079 | Skin | AK | regulation of microtubule cytoskeleton organization | 30/1910 | 148/18723 | 1.85e-04 | 2.12e-03 | 30 |
GO:00459306 | Skin | AK | negative regulation of mitotic cell cycle | 42/1910 | 235/18723 | 2.21e-04 | 2.46e-03 | 42 |
GO:000725410 | Skin | AK | JNK cascade | 32/1910 | 167/18723 | 3.38e-04 | 3.42e-03 | 32 |
GO:00435436 | Skin | AK | protein acylation | 42/1910 | 243/18723 | 4.59e-04 | 4.28e-03 | 42 |
GO:19019916 | Skin | AK | negative regulation of mitotic cell cycle phase transition | 33/1910 | 179/18723 | 5.67e-04 | 5.06e-03 | 33 |
GO:19019884 | Skin | AK | negative regulation of cell cycle phase transition | 42/1910 | 249/18723 | 7.65e-04 | 6.39e-03 | 42 |
GO:00000865 | Skin | AK | G2/M transition of mitotic cell cycle | 26/1910 | 137/18723 | 1.35e-03 | 1.00e-02 | 26 |
GO:19019836 | Skin | AK | regulation of protein acetylation | 17/1910 | 77/18723 | 1.66e-03 | 1.18e-02 | 17 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TAOK1 | SNV | Missense_Mutation | | c.1103N>G | p.Val368Gly | p.V368G | Q7L7X3 | protein_coding | deleterious(0.04) | probably_damaging(0.986) | TCGA-A2-A0YM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TAOK1 | SNV | Missense_Mutation | novel | c.2957C>A | p.Thr986Lys | p.T986K | Q7L7X3 | protein_coding | deleterious_low_confidence(0) | benign(0.198) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TAOK1 | SNV | Missense_Mutation | novel | c.2999N>C | p.Tyr1000Ser | p.Y1000S | Q7L7X3 | protein_coding | deleterious_low_confidence(0) | benign(0.021) | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
TAOK1 | SNV | Missense_Mutation | novel | c.3001N>T | p.Thr1001Ser | p.T1001S | Q7L7X3 | protein_coding | tolerated_low_confidence(0.75) | benign(0.003) | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
TAOK1 | SNV | Missense_Mutation | | c.2921N>G | p.Ser974Cys | p.S974C | Q7L7X3 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.838) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
TAOK1 | SNV | Missense_Mutation | | c.404N>G | p.Ala135Gly | p.A135G | Q7L7X3 | protein_coding | deleterious(0.04) | benign(0.057) | TCGA-D8-A142-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamid | SD |
TAOK1 | SNV | Missense_Mutation | | c.58T>C | p.Phe20Leu | p.F20L | Q7L7X3 | protein_coding | tolerated(0.6) | benign(0.058) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
TAOK1 | SNV | Missense_Mutation | novel | c.709N>G | p.Ile237Val | p.I237V | Q7L7X3 | protein_coding | deleterious(0) | possibly_damaging(0.811) | TCGA-LL-A6FP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
TAOK1 | insertion | Nonsense_Mutation | novel | c.84_85insTGAACTTTCACACCTGGCCT | p.Thr29Ter | p.T29* | Q7L7X3 | protein_coding | | | TCGA-B6-A0IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
TAOK1 | deletion | Frame_Shift_Del | novel | c.2425delC | p.Leu809TrpfsTer4 | p.L809Wfs*4 | Q7L7X3 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
57551 | TAOK1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, DNA REPAIR, ENZYME | | PHA-767491 | CHEMBL225519 | |
57551 | TAOK1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, DNA REPAIR, ENZYME | | PF-562271 | PF-00562271 | |
57551 | TAOK1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, DNA REPAIR, ENZYME | | TAE-684 | TAE-684 | |
57551 | TAOK1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, DNA REPAIR, ENZYME | | ENTRECTINIB | ENTRECTINIB | |
57551 | TAOK1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, DNA REPAIR, ENZYME | | LY-2090314 | LY-2090314 | |
57551 | TAOK1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, DNA REPAIR, ENZYME | | CENISERTIB | CENISERTIB | |
57551 | TAOK1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, DNA REPAIR, ENZYME | | DNDI1417467 | CHEMBL1997335 | |
57551 | TAOK1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, DNA REPAIR, ENZYME | | BMS-387032 | BMS-387032 | |
57551 | TAOK1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, DNA REPAIR, ENZYME | | LINIFANIB | LINIFANIB | |
57551 | TAOK1 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, DNA REPAIR, ENZYME | | BMS-345541 | BMS-345541 | |